Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000721273 | SCV000233203 | pathogenic | not provided | 2016-07-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000721273 | SCV000852297 | likely pathogenic | not provided | 2018-07-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492793 | SCV002788384 | likely pathogenic | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-11-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003591696 | SCV004285629 | pathogenic | RYR1-related disorder | 2023-06-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 199203). This premature translational stop signal has been observed in individual(s) with autosomal recessive RYR1-related conditions (PMID: 30155738). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change creates a premature translational stop signal (p.Glu4167*) in the RYR1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RYR1 are known to be pathogenic (PMID: 23919265, 25960145, 28818389, 30611313). |